Description

Product Description

Lanreotide diTFA is a synthetic analog of somatostatin, a naturally occurring peptide hormone that regulates endocrine and exocrine secretion. It is chemically modified as the di-trifluoroacetate (diTFA) salt to enhance solubility and stability in laboratory applications. Lanreotide binds to somatostatin receptors (SSTRs), particularly SSTR2 and SSTR5, and exhibits antineoplastic activity by inhibiting hormone release and modulating intracellular signaling pathways involved in tumor proliferation.

This peptide is extensively used in preclinical research for carcinoid syndrome, a condition characterized by hormone-secreting neuroendocrine tumors. By mimicking somatostatin’s inhibitory effects, Lanreotide diTFA reduces secretion of serotonin, vasoactive intestinal peptide (VIP), and other bioactive substances, providing a model to study symptom management and tumor biology. Its ability to regulate cellular proliferation and apoptosis allows researchers to explore mechanisms of tumor growth control in neuroendocrine contexts.

Lanreotide diTFA demonstrates high receptor selectivity and affinity, leading to reproducible inhibitory effects on hormone secretion and intracellular cAMP levels in vitro and in vivo. It is valuable for examining the role of somatostatin analogs in tumor suppression, signal transduction, and endocrine feedback loops, including interactions with growth hormone, insulin, and glucagon.

The peptide’s GMP-grade production ensures high purity, consistent batch quality, and stability, crucial for reproducible experimental results. Supplied as a lyophilized powder, Lanreotide diTFA maintains structural integrity under standard laboratory storage conditions. Researchers can conduct long-term experiments in cellular assays, isolated tissue systems, and animal models of carcinoid syndrome and neuroendocrine tumor growth.

In translational research, Lanreotide diTFA is used to study tumor growth inhibition, hormone regulation, receptor pharmacology, and therapeutic analog development. Its dual action on hormone secretion and cell proliferation makes it an indispensable tool for laboratories investigating novel interventions for neuroendocrine tumors.

?? Disclaimer: For laboratory research use only. Not for human or veterinary use.

Product Specifications

Lanreotide diTFA’s specifications provide researchers with high-quality, reproducible peptide material suitable for a wide range of experiments in neuroendocrine and oncological research.

Mechanism of Action & Research Applications

Lanreotide diTFA functions primarily as a somatostatin receptor (SSTR) agonist, binding selectively to SSTR2 and SSTR5, which are highly expressed in neuroendocrine tissues and certain tumors. Receptor activation leads to inhibition of adenylate cyclase, reduced cAMP levels, modulation of calcium flux, and downstream suppression of hormone secretion. These effects result in reduced proliferation of neuroendocrine tumor cells and attenuation of hormone-mediated symptoms in carcinoid syndrome models.

Mechanism Overview:

1. Receptor Binding and Selectivity
   Lanreotide diTFA binds with high affinity to SSTR2 and SSTR5, ensuring targeted inhibition of hormone-secreting tumor cells without significant off-target effects.

2. Inhibition of Hormone Secretion
   Activation of SSTRs suppresses secretion of serotonin, VIP, gastrin, and other bioactive molecules, reducing symptom burden in carcinoid syndrome models.

3. Antiproliferative Effects
   Through modulation of intracellular signaling, including MAPK and PI3K/AKT pathways, Lanreotide diTFA can slow cell cycle progression and induce apoptosis in tumor cells.

4. Endocrine Feedback Modulation
   The peptide impacts growth hormone, insulin, and glucagon regulation, making it valuable for studying endocrine system dynamics and tumor-endocrine interactions.

Research Applications:

• Carcinoid Syndrome Studies
  Models the suppression of hormone overproduction, allowing analysis of symptom control mechanisms.

• Neuroendocrine Tumor Research
  Investigates antiproliferative effects, apoptosis induction, and receptor-mediated growth inhibition.

• Mechanistic Signal Transduction Studies
  Evaluates SSTR-mediated cAMP inhibition, calcium flux modulation, and downstream signaling in cellular models.

• Translational Oncology Research
  Provides preclinical insights into novel therapies for neuroendocrine tumors, including somatostatin analog-based interventions.

• Combination Therapy Models
  Allows assessment of synergy with chemotherapeutic agents or targeted molecular therapies in vitro and in vivo.

• Pharmacokinetics and Dose-Response Studies
  Supports characterization of receptor binding, peptide stability, and dose-dependent efficacy in research models.

• Endocrine System Modeling
  Useful for studies of feedback loops between pancreas, pituitary, and tumor cells, elucidating regulatory pathways.

Lanreotide diTFA’s dual effects on hormone modulation and antiproliferative activity provide a versatile platform for comprehensive preclinical research into neuroendocrine disorders and targeted peptide therapeutics.

Side Effects (For Reference in Research Models)

Experimental observations in laboratory models include:

• Hormone Suppression Effects
  Dose-dependent reduction in serotonin, VIP, and other hormones.

• Gastrointestinal Effects
  Mild reductions in motility or secretory activity observed in rodent models.

• Hepatic and Renal Responses
  Modulation of liver enzyme activity or renal filtration markers can occur in high-dose studies.

• Cardiovascular Parameters
  Slight transient effects on heart rate or blood pressure may be observed in vivo.

• Pharmacokinetic Considerations
  Peptide stability is maintained in lyophilized form; repeated freeze-thaw cycles should be avoided.

• Experimental Model Observations
  Variability in hormonal suppression or tumor inhibition may occur depending on species, dose, and experimental design.

?? These effects are strictly for laboratory research reference. Lanreotide diTFA is not intended for human or veterinary use. Researchers should follow institutional safety protocols when handling the peptide.

Disclaimer

For laboratory research use only. Not for human or veterinary use.

Keywords

• Lanreotide diTFA

• Lanreotide CAS 1024499-83-9

• BIM 23014 peptide

• Somatostatin analog research peptide

• Carcinoid syndrome research compound

• GMP supplier Lanreotide

• Neuroendocrine tumor peptide

• Hormone modulation research

• Preclinical oncology peptide

• Laboratory endocrine research peptide